Search results for " dose"

showing 10 items of 593 documents

[Non-indicated insulin treatment].

1970

171 adult- and aged-onset diabetic patients treated with insulin primarily or secondarily were subjected to an attempted therapy with the additional administration of oral antidiabetic drugs. The new potent antidiabetic drug, glybenclamide (HB 419 = Daonil), was employed on a vast scale in order to carry out an oral monotherapy in the proper indications also combined with biguanides. In the 52 % of patients in study with the additional oral therapy the insulin dose could be remarkably decreased, in the 24 % of cases insulin could be at all abolished. In another 24 % of controlled cases no decrease in insulin need was found. A body weight decrease could be obtained rather in the group of pat…

DrugAdultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectmedicine.medical_treatmentPharmacologyBody weightInsulin doseEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineDiabetes MellitusHumansHypoglycemic AgentsInsulinShort durationOral therapymedia_commonAgedbusiness.industryInsulinGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologyWeight DecreasebusinessActa diabetologica latina
researchProduct

Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

2020

Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of peo…

Drugmedicine.medical_specialtyPost exposureCoronavirus disease 2019 (COVID-19)COVID19media_common.quotation_subject030231 tropical medicineHydroxychloroquine ; COVID-19 ; Chloroquine ; SARS-CoV2 ; antiviral ; malaria ; Systemic lupus erythematosus ; Immunomodulation ; CoronavirusLoading doseImmunomodulation03 medical and health sciencesSystemic lupus erythematosus0302 clinical medicineChloroquineInternal medicineMedicine030212 general & internal medicineCoronavirus malaria antiviralmedia_commonlcsh:R5-920business.industryStandard treatmentPublic Health Environmental and Occupational HealthChloroquineHydroxychloroquineClinical trialEditorialInfectious DiseasesSARS-CoV2lcsh:Medicine (General)businessHydroxychloroquinemedicine.drugOne Health
researchProduct

Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.

2020

Inhalation therapy allows conveying drugs directly into the airways. The devices used to administer inhaled drugs play a crucial role in the management of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). To ensure high bronchial deposition of the drug, a device should deliver a high proportion of fine particles, be easy to use, and provide constant and accurate doses of the active substance. Nowadays, four different types of inhalers are widely used: nebulizers, dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Nebulizers can be used by patients unable to use other inhalers. However, they require l…

Drugmedicine.medical_specialtyRespiratory TherapyRespimatmedia_common.quotation_subjectSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyMDI03 medical and health sciencesRoute of administrationPulmonary Disease Chronic Obstructive0302 clinical medicineAsthma COPD DPI MDI Nebulizer RespimatAdministration InhalationInternal MedicinemedicineCOPDHumans030212 general & internal medicineMetered Dose InhalersIntensive care medicineAsthmamedia_commonCOPDInhalationbusiness.industryInhalerNebulizers and VaporizersNebulizerEquipment Designmedicine.diseaseAsthma; COPD; DPI; MDI; Nebulizer; RespimatAsthmaRespimatDPINebulizerbusinessEuropean journal of internal medicine
researchProduct

Minimum effective dose for antidepressants - an obligatory requirement for antidepressant drug evaluation?

1996

Extensive clinical trials are required for registration and approval of new antidepressants in most countries including the requirement that a minimal effective dose should be determined. The rationale for this requirement is to avoid the use of unnecessarily high doses. The implication is that for every antidepressant, a dose exists that serves as a threshold, below which all doses are not effective or are clearly less effective in treating a major depressive episode. Dose titration and fixed dose studies are used to determine the minimal effective dose, but both strategies have limitations and often do not allow definite establishment of a clear-cut minimal effective dose. The effort of e…

Drugmedicine.medical_specialtymedia_common.quotation_subjectComorbidityPharmacologyPharmacokineticsmedicineHigh dosesHumansEthics MedicalPharmacology (medical)Intensive care medicineMajor depressive episodemedia_commonClinical Trials as TopicDepressive DisorderDose-Response Relationship Drugbusiness.industryConfounding Factors EpidemiologicEffective dose (pharmacology)Antidepressive AgentsClinical trialPsychiatry and Mental healthSample size determinationAntidepressantmedicine.symptombusinessInternational Clinical Psychopharmacology
researchProduct

Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature.

2018

Objectives To review the available evidence concerning the possibility of discontinuing and/or tapering the dosage of TNF inhibitors (TNFi) in RA patients experiencing clinical remission or low disease activity. Methods A systematic review of the literature concerning the low dosage and discontinuation of TNFi in disease-controlled RA patients was performed by evaluation of reports published in indexed international journals (Medline via PubMed, EMBASE), in the time frame from 8 April 2013 to 15 January 2016. Results We analysed the literature evaluating the efficacy and the safety of two different strategies using TNFi, decreasing dosage or discontinuation, in patients experiencing clinica…

Drugmedicine.medical_specialtymedia_common.quotation_subjectMEDLINEArthritisEtanerceptDose-Response RelationshipArthritis Rheumatoid03 medical and health sciences0302 clinical medicineRheumatologyRheumatoidInternal medicinemedicineAdalimumabHumansPharmacology (medical)030212 general & internal medicinemedia_common030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisRemission Inductionmedicine.diseaseRheumatologyAntirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Humans; Remission Induction; Tumor Necrosis Factor-alpha; Rheumatology; Pharmacology (medical)DiscontinuationRheumatoid arthritisAntirheumatic AgentsDrugbusinessmedicine.drugRheumatology (Oxford, England)
researchProduct

Levels of 137Cs in game and soil in Opole Anomaly, Poland in 2012–2020

2021

Abstract Once deposited, radiocesium remains in the environment for a long time, and constantly enters the food chain. Over time, game species tend to accumulate 137Cs by two orders of magnitude more than farm animals. This occurs especially in places heavily contaminated, thus meat products made out of local game should be treated with caution. One of such areas, known as the Opole Anomaly, is located in South-Western Poland and represents one of most 137Cs contaminated regions across Europe after the Chernobyl accident. The aim of the study was to find out the 137Cs activity in soil and local game, the value of the soil-to-game aggregated transfer factor and to assess the effective dose o…

Effective dosebiology137CsHealth Toxicology and MutagenesisPublic Health Environmental and Occupational HealthGameAggregated transfer factorOpole AnomalyGeneral MedicinePollutionEnvironmental pollutionChernobylToxicologyRoe deerEnvironmental sciencesFood chainGeographyWild boarTD172-193.5biology.animalGE1-350Ecotoxicology and Environmental Safety
researchProduct

The "Livio Scarsi" X-Ray Facility at University of Palermo for Device Testing

2015

In this work, we report on the characteristics of the Livio Scarsi X-ray facility at University of Palermo. The facility is able to produce low energy X rays, within the energy range of 0.1-60 keV, with fluence rates ranging from 105-108 photons/mm2 s. The laboratory is equipped with an innovative digital detection system, based on semiconductor detectors (Si and CdTe detectors), able to provide accurate and precise estimation of the fluence rate, the energy and the exposure of X rays, even at high counting rate conditions. Instrumentation for electrical characterization (DC-AC) of semiconductor devices, for both off-line and on-line (i.e. during the irradiation) measurements, is also avail…

EngineeringPhotonbusiness.industrySettore FIS/01 - Fisica SperimentaleX-rayGamma raySemiconductor deviceFluenceSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Semiconductor detectorX-ray facility semiconductor detectors digital pulse processing rad-hard MOSFETs total ionizing testsOpticsAbsorbed doseIrradiationbusinessTelecommunications2015 15th European Conference on Radiation and Its Effects on Components and Systems (RADECS)
researchProduct

Effect of the lipid regulator Gemfibrozil in the Cladocera Daphnia magna at different temperatures.

2016

ABSTRACTIn the present study, an ecotoxicological approach to the evaluation of Gemfibrozil (GEM) as an emerging organic pollutant was done. In order to assess its toxicity, tests were conducted using the cladocera Daphnia magna. Experiments were carried out at 22°C and 28°C. EC50, feeding behavior, and chronic toxicity tests (21 days) were evaluated in D. magna exposed to GEM as well as cholesterol levels at 21-day chronic exposure. D. magna GEM EC50 values (24 h) in our experimental conditions were 148.75 and 116.24 mg L−1 at 22°C and 28°C, respectively. Test concentrations of 0.1, 0.5, 1.0, 5.0 and 7.5 mg L−1 were selected for subacute and chronic experiments. Subacute short-term test (f…

Environmental EngineeringDaphnia magna010501 environmental sciences01 natural sciencesToxicologyLethal Dose 5003 medical and health scienceschemistry.chemical_compound0302 clinical medicineAnimal sciencemedicineGemfibrozilIngestionAnimalsToxicity Tests ChronicChronic toxicity0105 earth and related environmental sciencesEC50Hypolipidemic AgentsbiologyReproductionTemperatureGeneral MedicineFeeding Behaviorbiology.organism_classificationCladocerachemistryDaphnia030220 oncology & carcinogenesisToxicityFemaleGemfibrozilWater Pollutants Chemicalmedicine.drugToxicantJournal of environmental science and health. Part A, Toxic/hazardous substancesenvironmental engineering
researchProduct

Chromatographic retention–activity relationships for prediction of the toxicity pH-dependence of phenols

2007

Abstract An investigation of the use of the chromatographic retention (log  k ) as an in vitro approach for modeling the pH-dependence of the toxicity to Guppy of phenols is developed. A data set of 19 phenols with available experimental toxicity–pH data was used. The importance of the mechanism of toxic action (MOA) of phenols was studied. log  k data at three pH values were used for the phenols classification and two groups or ‘MODEs’ were identified. For one ‘MODE’ a quantitative retention–activity relationship (QRAR) model was calculated. Finally, the model was used to assess the toxicity to Guppy of phenols at different pH values. The results of this investigation suggest that chromato…

Environmental EngineeringHealth Toxicology and MutagenesisQuantitative Structure-Activity RelationshipModels BiologicalLethal Dose 50chemistry.chemical_compoundPhenolsPh dependenceAnimalsEnvironmental ChemistryOrganic chemistryEcotoxicologyPhenolsChromatographyPoeciliaChromatographyChemistryPublic Health Environmental and Occupational HealthGeneral MedicineGeneral ChemistryHydrogen-Ion ConcentrationPollutionToxicityPh rangeFish <Actinopterygii>ForecastingChemosphere
researchProduct

Clinical microbeam radiation therapy with a compact source: specifications of the line-focus X-ray tube

2020

Highlights • Line-focus X-ray tubes are suitable for clinical microbeam radiation therapy (MRT). • A modular high-voltage supply safely enables high electron beam powers. • An electron accelerator was designed to generate an eccentric focal spot. • We simulated a peak-to-valley dose ratio above 20 for single-field MRT. • Microbeam arc therapy spares healthy brain tissue compared to single-field MRT.

Equivalent uniform doselcsh:Medical physics. Medical radiology. Nuclear medicineMaterials scienceCompact radiation sourcelcsh:R895-920Monte Carlo methodElectronlcsh:RC254-282030218 nuclear medicine & medical imaginglaw.inventionCompact Radiation Source ; Equivalent Uniform Dose ; Line-focus X-ray Tube ; Microbeam Arc Therapy ; Microbeam Radiation Therapy ; Modular High-voltage Supply03 medical and health sciences0302 clinical medicineOpticslawRadiology Nuclear Medicine and imagingFocal Spot SizeOriginal Research ArticleLine-focus X-ray tubeRange (particle radiation)Radiationbusiness.industryMicrobeam arc therapyMicrobeamHot cathodeModular high-voltage supplyX-ray tubeequipment and supplieslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030220 oncology & carcinogenesisCathode raybusinessMicrobeam radiation therapyPhysics and Imaging in Radiation Oncology
researchProduct